The latest report by IMARC Group, titled “Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the global vaccine market share. The report also includes competitor and regional analysis, and contemporary advancements in the global market.
The global vaccine market is expected to exhibit a CAGR of 10.33% during 2022-2027. A vaccine represents a biological component that stimulates the production of antibodies against various harmful pathogens present in the body. It is primarily manufactured by utilizing disease-causing agents and chemical drugs which act as antigens. Some of the commonly available product variants in the market include inactivated, conjugate, toxoid, live attenuated, recombinant, etc. Furthermore, a vaccine assists in protecting the body against several life-threatening diseases, such as polio, measles, tetanus, diphtheria, meningitis, etc. Consequently, it is extensively used in immunization procedures across hospitals, clinics, vaccination centers, etc.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Request Free Sample Report: https://www.imarcgroup.com/vaccine-market/requestsample
Important Attribute and highlights of the Report:
- Detailed analysis of the global market share
- Market Segmentation
- Historical, current, and projected size of the market in terms of volume and value
- Latest industry trends and developments
- Competitive Landscape
- Strategies of major players and product offerings
Global Vaccine Market Trends and Drivers:
The rising consumer awareness towards the importance of adequate immunization for eradicating numerous infections is primarily driving the vaccine market. Additionally, the increasing number of child deaths, on account of the growing prevalence of infectious diseases, such as hepatitis, polio, rubella, etc., is inflating the need for adequate vaccination facilities in the endemic regions, which, in turn, is further catalyzing the market growth. Besides this, the widespread adoption of vaccines for research purposes in academic and clinical laboratories is acting as another significant growth-inducing factor. Moreover, the launch of numerous favorable policies by government bodies across countries to promote free seasonal influenza vaccination programs for individuals of all age groups is also bolstering the global market. Apart from this, the introduction of advanced and improved product variants that are produced by accelerating the clinical trials of various pipeline drugs, owing to the sudden outbreak of the COVID-19 pandemic, is anticipated to fuel the vaccines market over the forecasted period.
Explore Full Report with TOC & List of Figures: https://www.imarcgroup.com/vaccine-market
Key Market Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- Abbott Laboratories
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bharat Biotech International Limited
- Bavarian Nordic A/S
- CSL Limited
- Daiichi Sankyo Company, Limited
- Emergent BioSolutions Inc.
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals Inc.
- Johnson & Johnson, Inc.
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Holdings Corporation)
- Novavax Inc.
- Panacea Biotec Ltd.
- Pfizer Inc.
- Sanofi Pasteur SA (Sanofi SA)
- Serum Institute of India Pvt. Ltd.
- Takeda Pharmaceutical Company Limited
Breakup by Technology:
- Conjugate Vaccines
- Inactivated and Subunit Vaccines
- Live Attenuated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
Breakup by Patient Type:
Breakup by Indication:
- Bacterial Diseases
- Meningococcal Disease
- Pneumococcal Disease
- Diphtheria/Tetanus/Pertussis (DPT)
- Haemophilus Influenzae (Hib)
- Viral Diseases
- Human Papillomavirus (HPV)
- Measles/Mumps/Rubella (MMR)
- Herpes Zoster
- Japanese Encephalitis
Breakup by Route of Administration:
- Intramuscular and Subcutaneous Administration
- Oral Administration
Breakup by Product Type:
- Multivalent Vaccine
- Monovalent Vaccine
Breakup by Treatment Type:
- Preventive Vaccine
- Therapeutic Vaccine
Breakup by End User:
- Vaccination Centres
- Academic and Research Institutes
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Institutional Sales
Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)
Key highlights of the Report:
- Market Performance (2016-2021)
- Market Outlook (2022-2027)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
TOC for the Report:
- Scope and Methodology
- Executive Summary
- Global Market
- SWOT Analysis
- Value Chain Analysis
- Price Analysis
- Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800